← Journal of Immunotherapy and Precision Oncology
Papers in Journal of Immunotherapy and Precision Oncology
Page 1 · newest first
- Releasing Immunosuppression in the Tumor: A Phase 1/2 Study of Arginase Inhibitor INCB001158 in Combination with Chemotherapy in Advanced MalignanciesJournal of Immunotherapy and Precision Oncology · 2026
- Outcomes of Patients with Rare Cancers Treated with Immune Checkpoint Inhibitors with and Without Lung and/or Liver Metastases (NCI/SWOG S1609)Journal of Immunotherapy and Precision Oncology · 2026
- Molecular Profiling in Asia: The Current Status and ApproachJournal of Immunotherapy and Precision Oncology · 2026
- Molecular Profiling and Precision Oncology for Non–Small Cell Lung Cancer in Latin America: Unique Epidemiology, Persistent Barriers, and Paths Toward EquityJournal of Immunotherapy and Precision Oncology · 2026
- State of Precision Oncology: An Australian PerspectiveJournal of Immunotherapy and Precision Oncology · 2026
- The Immune Checkpoint Inhibitors Journey: From Early Promise to Lasting ImpactJournal of Immunotherapy and Precision Oncology · 2026
- The Double-Edged Role of Social Media in Modern Healthcare: Awareness, Impact, and MisinformationJournal of Immunotherapy and Precision Oncology · 2026
- AXL Inhibitors in Oncology Clinical Trials: A ReviewJournal of Immunotherapy and Precision Oncology · 2025
- Replication-Competent, Tumor-Specific Immuno-Gene Vectors Allow for Exchange of Transgenes and Lead to Viral Persistence Following IV AdministrationJournal of Immunotherapy and Precision Oncology · 2025
- Phase 2 Study of Monotherapy with Pembrolizumab for Advanced Adrenocortical CarcinomaJournal of Immunotherapy and Precision Oncology · 2025
- Exceptional Response to Immunotherapy-based Treatment in Compound EGFR-Mutated Oligometastatic Pulmonary Sarcomatoid Carcinoma: A Case ReportJournal of Immunotherapy and Precision Oncology · 2025
- Circulating Tumor DNA as a Prognostic Biomarker for Selecting Participants to Early Phase Clinical TrialsJournal of Immunotherapy and Precision Oncology · 2025
- Prevalence of Molecular Mutations in Non–Small Cell Lung Cancer and Current Treatment Approaches in the MENA Region: Systematic Review and Expert OpinionJournal of Immunotherapy and Precision Oncology · 2025
- Immunotherapy and Targeted Therapies in Sarcoma: Proposed Synergy with Combination TreatmentJournal of Immunotherapy and Precision Oncology · 2025
- Exceptional Response in a Patient with mRCC Through Precision-Guided Treatment Involving Immunotherapy Rechallenge with Temsirolimus and BevacizumabJournal of Immunotherapy and Precision Oncology · 2025
- Anti–PD-1 Therapy for Patients with Advanced Cholangiocarcinoma: Ready for Prime Time?Journal of Immunotherapy and Precision Oncology · 2025
- Selinexor in Uveal Melanoma: A Hopeful Step or Just Another Hurdle?Journal of Immunotherapy and Precision Oncology · 2025
- Olaparib and Durvalumab in Patients with DNA Damage Repair Alterations and Biochemically Recurrent Prostate CancerJournal of Immunotherapy and Precision Oncology · 2025
- Major Adverse Cardiovascular Events in Patients with Melanoma Receiving Immune Checkpoint InhibitorsJournal of Immunotherapy and Precision Oncology · 2025
- Pembrolizumab in Patients with Advanced Miscellaneous Rare Cancers: Results from a Phase 2 Basket TrialJournal of Immunotherapy and Precision Oncology · 2025
- B7 Homolog 4 (B7-H4)-Directed Agents in Oncology Clinical Trials: A ReviewJournal of Immunotherapy and Precision Oncology · 2025
- 4-1BB Antibodies in Oncology Clinical Trials: A ReviewJournal of Immunotherapy and Precision Oncology · 2025
- Advancing Understanding and Therapeutic Strategies for NUT Sarcomas: Comprehensive Review of the Literature and Two CasesJournal of Immunotherapy and Precision Oncology · 2025
- Incidence and Factors Associated with Graft-Versus-Host Disease in the First Year After Allogeneic Peripheral Blood Stem Cell TransplantationJournal of Immunotherapy and Precision Oncology · 2025
- Lefitolimod in Combination with Ipilimumab in Patients with Advanced Solid Tumors: A Phase I TrialJournal of Immunotherapy and Precision Oncology · 2025
- Treatment of c-MET Antibody-Drug Conjugate Asymptomatic Pneumonitis with a Novel Steroid Regimen in Non–Small Cell Lung Cancer: A Case ReportJournal of Immunotherapy and Precision Oncology · 2025
- Safety and Efficacy of Toripalimab in Patients with Cholangiocarcinoma: An Open-Label, Phase 1 StudyJournal of Immunotherapy and Precision Oncology · 2025
- Selinexor (KPT-330) in Combination with Immune Checkpoint Inhibition in Uveal Melanoma: A Phase 1B TrialJournal of Immunotherapy and Precision Oncology · 2025
- Expert Clinical Management of Inflammatory Immune-Related Arthritis in Patients with Cancer Receiving Immune Checkpoint InhibitorsJournal of Immunotherapy and Precision Oncology · 2025
- Usefulness of Comprehensive Genomic Profiling in Clinical Decision-Making in Oncology: A Systematic ReviewJournal of Immunotherapy and Precision Oncology · 2025
- More Than Medicine: The Hope, Hurdles, and Hidden Costs of IgG TherapyJournal of Immunotherapy and Precision Oncology · 2025
- Cyclin Dependent Kinase 2 (CDK2) Inhibitors in Oncology Clinical Trials: A ReviewJournal of Immunotherapy and Precision Oncology · 2024
- Use of Immunoglobulin Replacement Therapy in Clinical Practice: A ReviewJournal of Immunotherapy and Precision Oncology · 2024
- Oncology Clinical Trials Targeting Members of the Cadherin Superfamily: A ReviewJournal of Immunotherapy and Precision Oncology · 2024
- A Rare But Fatal Toxicity: Immune Checkpoint Inhibitor–Related Acquired Thrombotic Thrombocytopenic PurpuraJournal of Immunotherapy and Precision Oncology · 2024
- A Comprehensive Exploration of Agents Targeting Tumor Microenvironment: Challenges and Future PerspectivesJournal of Immunotherapy and Precision Oncology · 2024
- Durable Remission After Targeted Therapy in BRAF V600E–Mutant Metastatic Colorectal Cancer: Case ReportJournal of Immunotherapy and Precision Oncology · 2024
- Real-World Outcomes in Patients with Advanced Penile Squamous Cell Carcinoma Receiving Immune Checkpoint Inhibitors: A Single Institution ExperienceJournal of Immunotherapy and Precision Oncology · 2024
- Circulating Galectin-3: A Prognostic Biomarker in Hepatocellular CarcinomaJournal of Immunotherapy and Precision Oncology · 2024
- Advanced Granulosa Cell Tumors of the Ovary: A Review with a Focus on Current and Novel Therapeutic ApproachesJournal of Immunotherapy and Precision Oncology · 2024
- Unexpected Mediastinal Mass Etiology in B-Acute Lymphoblastic LeukemiaJournal of Immunotherapy and Precision Oncology · 2024
- Updates in Drug-Related Pneumonitis Due to Targeted Oncologic TherapiesJournal of Immunotherapy and Precision Oncology · 2024
- A Phase Ib Study of Selinexor in Combination with Pembrolizumab in Patients with Metastatic MelanomaJournal of Immunotherapy and Precision Oncology · 2024
- Successful Targeting of Somatic VHL Alterations With Belzutifan in Two CasesJournal of Immunotherapy and Precision Oncology · 2024
- Diaphragmatic Myopathy Associated with Dual Immune Checkpoint Inhibitors in a Patient with Renal Cell CarcinomaJournal of Immunotherapy and Precision Oncology · 2024
- Case Series: EGFR and ROS-1 Co-Occurrence in Advanced Non–Small Cell Lung CancerJournal of Immunotherapy and Precision Oncology · 2024
- Abstracts Presented at the 2024 WIN Symposium in Partnership with Burjeel Holdings: March 1–2 Abu Dhabi, United Arab EmiratesJournal of Immunotherapy and Precision Oncology · 2024
- Decentralized Clinical Trials in Early Drug Development—A Framework ProposalJournal of Immunotherapy and Precision Oncology · 2024
- Overcoming Tagraxofusp-Erzs Monotherapy Resistance in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) in a Real-World Clinical SettingJournal of Immunotherapy and Precision Oncology · 2024
- Impact of COVID-19 on Management and Outcomes of Oncology Patients: Results of MENA COVID-19 and Cancer Registry (MCCR)Journal of Immunotherapy and Precision Oncology · 2024